Crescent Biopharma, Inc. (CBIO) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Crescent Biopharma, Inc. (CBIO) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $573.2M, listed on NASDAQ, employing roughly 41 people, carrying a beta of 1.20 to the broader market. Crescent Biopharma, Inc. Led by Joshua T. Brumm, public since 2014-01-10.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for CBIO as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.